CONMED Corporation (CNMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $1.51B
Last updated: Nov 17, 2026 at 11:04 AM ET
CONMED Corporation (CNMD) Earnings: Report Dates and Results
CONMED (CNMD) is expected to report earnings on Jan 26, 2027. In the quarter ended Sep 30, 2026, CONMED reported EPS of $1.04, above the $1.00 estimate. It beat the EPS estimate in each of the last 11 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CNMD has an expected report date of Jan 26, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 9.8% below the $1.43 reported for the quarter ended Dec 31, 2025.
CNMD Earnings Call
The latest CNMD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CNMD beat 35, missed 3 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $335.56M, down 0.7% from $337.93M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.04 | $1.00 | $0.99 - $1.02 | +4.00% | Beat | -3.7% | 7 | N/A | Oct 28, 2026 | $335.56M |
| Jun 30, 2026 | $1.38 | $1.10 | $1.07 - $1.12 | +25.45% | Beat | +20.0% | 7 | 1 up, 0 down | Jul 29, 2026 | $343.49M |
| Mar 31, 2026 | $0.89 | $0.82 | $0.81 - $0.83 | +8.54% | Beat | -6.3% | 5 | 0 up, 3 down | Apr 29, 2026 | $317.05M |
| Dec 31, 2025 | $1.43 | $1.32 | $1.31 - $1.33 | +8.33% | Beat | +6.7% | 6 | 0 up, 0 down | Jan 28, 2026 | $373.20M |
| Sep 30, 2025 | $1.08 | $1.05 | $1.04 - $1.06 | +2.86% | Beat | +2.9% | 6 | 4 up, 0 down | Nov 5, 2025 | $337.93M |
| Jun 30, 2025 | $1.15 | $1.12 | $1.10 - $1.14 | +2.68% | Beat | +17.3% | 6 | 7 up, 0 down | Jul 30, 2025 | $342.35M |
| Mar 31, 2025 | $0.95 | $0.81 | $0.80 - $0.83 | +17.28% | Beat | +20.3% | 7 | 0 up, 5 down | Apr 30, 2025 | $321.26M |
| Dec 31, 2024 | $1.34 | $1.20 | $1.17 - $1.21 | +11.67% | Beat | +26.4% | 7 | 0 up, 1 down | Feb 5, 2025 | $345.94M |
| Sep 30, 2024 | $1.05 | $1.00 | $0.98 - $1.01 | +5.00% | Beat | +16.7% | 8 | 2 up, 0 down | Oct 30, 2024 | $316.70M |
| Jun 30, 2024 | $0.98 | $0.91 | $0.88 - $0.99 | +7.69% | Beat | +18.1% | 8 | 0 up, 1 down | Jul 31, 2024 | $332.10M |
| Mar 31, 2024 | $0.79 | $0.74 | $0.73 - $0.74 | +6.76% | Beat | +19.7% | 8 | 0 up, 0 down | Apr 24, 2024 | $312.27M |
| Dec 31, 2023 | $1.06 | $1.11 | $1.10 - $1.12 | -4.50% | Miss | +152.4% | 8 | 0 up, 0 down | Jan 31, 2024 | $327.05M |
| Sep 30, 2023 | $0.90 | $0.83 | $0.82 - $0.84 | +8.43% | Beat | +16.9% | 8 | 0 up, 0 down | Oct 25, 2023 | $304.58M |
| Jun 30, 2023 | $0.83 | $0.79 | $0.78 - $0.81 | +5.06% | Beat | +9.2% | 9 | 1 up, 0 down | Jul 26, 2023 | $317.65M |
| Mar 31, 2023 | $0.66 | $0.60 | $0.58 - $0.61 | +10.00% | Beat | -5.7% | 8 | 0 up, 0 down | Apr 26, 2023 | $295.47M |
| Dec 31, 2022 | $0.42 | $0.90 | $0.78 - $1.03 | -53.33% | Miss | -60.7% | 7 | 0 up, 0 down | Feb 2, 2023 | $250.87M |
| Sep 30, 2022 | $0.77 | $0.75 | $0.72 - $0.78 | +2.67% | Beat | -3.8% | 7 | 0 up, 1 down | Oct 26, 2022 | $275.09M |
| Jun 30, 2022 | $0.76 | $0.75 | $0.69 - $0.83 | +1.33% | Beat | +7.0% | 6 | 0 up, 1 down | Jul 27, 2022 | $277.19M |
| Mar 31, 2022 | $0.70 | $0.62 | $0.55 - $0.65 | +12.90% | Beat | +11.1% | 6 | 0 up, 0 down | May 4, 2022 | $242.33M |
| Dec 31, 2021 | $1.07 | $1.03 | N/A | +3.88% | Beat | +27.4% | 6 | 0 up, 0 down | Jan 26, 2022 | $273.97M |
| Sep 30, 2021 | $0.80 | $0.75 | $0.67 - $0.81 | +6.67% | Beat | -9.1% | 8 | N/A | Oct 27, 2021 | $248.83M |
| Jun 30, 2021 | $0.71 | $0.62 | $0.59 - $0.65 | +14.52% | Beat | N/A | 8 | N/A | Jul 28, 2021 | $255.16M |
| Mar 31, 2021 | $0.63 | $0.44 | $0.43 - $0.45 | +43.18% | Beat | +23.5% | 6 | N/A | Apr 28, 2021 | $232.68M |
| Dec 31, 2020 | $0.84 | $0.77 | $0.70 - $0.93 | +9.09% | Beat | -6.7% | 6 | N/A | Jan 27, 2021 | $252.83M |
| Sep 30, 2020 | $0.88 | $0.23 | -$0.09 - $0.45 | +282.61% | Beat | +41.9% | 6 | N/A | Oct 28, 2020 | $237.84M |
| Jun 30, 2020 | -$0.07 | -$0.95 | -$1.52 - -$0.69 | +92.63% | Beat | -112.5% | 7 | N/A | Jul 29, 2020 | $157.78M |
| Mar 31, 2020 | $0.51 | $0.44 | $0.09 - $0.61 | +15.91% | Beat | -10.5% | 7 | N/A | Apr 29, 2020 | $214.01M |
| Dec 31, 2019 | $0.90 | $0.89 | $0.88 - $0.89 | +1.12% | Beat | +23.3% | 7 | N/A | Jan 29, 2020 | $264.87M |
| Sep 30, 2019 | $0.62 | $0.56 | $0.54 - $0.58 | +10.71% | Beat | +34.8% | 6 | N/A | Oct 30, 2019 | $233.59M |
| Jun 30, 2019 | $0.56 | $0.53 | $0.52 - $0.55 | +5.66% | Beat | +21.7% | 6 | N/A | Jul 31, 2019 | $238.26M |
| Mar 31, 2019 | $0.57 | $0.54 | $0.52 - $0.54 | +5.56% | Beat | +7.5% | 5 | N/A | Apr 24, 2019 | $218.38M |
| Dec 31, 2018 | $0.73 | $0.73 | $0.72 - $0.74 | 0.00% | In line | +5.8% | 5 | N/A | Jan 22, 2019 | $242.44M |
| Sep 30, 2018 | $0.46 | $0.45 | $0.40 - $0.48 | +2.22% | Beat | +9.5% | 5 | N/A | Nov 1, 2018 | $202.31M |
| Jun 30, 2018 | $0.46 | $0.45 | $0.45 - $0.46 | +2.22% | Beat | +12.2% | 4 | N/A | Aug 1, 2018 | $212.82M |
| Mar 31, 2018 | $0.53 | $0.43 | $0.42 - $0.46 | +23.26% | Beat | +39.5% | 5 | N/A | Apr 25, 2018 | $202.06M |
| Dec 31, 2017 | $0.69 | $0.65 | $0.64 - $0.67 | +6.15% | Beat | +27.8% | 5 | N/A | Jan 31, 2018 | $222.55M |
| Sep 30, 2017 | $0.42 | $0.41 | $0.39 - $0.43 | +2.44% | Beat | +2.4% | 6 | N/A | Nov 2, 2017 | $190.12M |
| Jun 30, 2017 | $0.41 | $0.41 | $0.39 - $0.42 | 0.00% | In line | +13.9% | 6 | N/A | Jul 26, 2017 | $197.15M |
| Mar 31, 2017 | $0.38 | $0.35 | N/A | +8.57% | Beat | +26.7% | N/A | N/A | Apr 26, 2017 | $186.57M |
| Dec 31, 2016 | $0.54 | $0.56 | N/A | -3.57% | Miss | +3.8% | N/A | N/A | Feb 1, 2017 | $204.09M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $4.61, up 10.8% from the year before. It was $1.61 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $4.61 | +10.8% |
| Dec 31, 2024 | $4.16 | +20.6% |
| Dec 31, 2023 | $3.45 | +30.2% |
| Dec 31, 2022 | $2.65 | -17.4% |
| Dec 31, 2021 | $3.21 | +48.6% |
| Dec 31, 2020 | $2.16 | -18.5% |
| Dec 31, 2019 | $2.65 | +21.6% |
| Dec 31, 2018 | $2.18 | +14.7% |
| Dec 31, 2017 | $1.90 | +18.0% |
| Dec 31, 2016 | $1.61 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,000 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,009 | 11 | |
| 2026Q2 | Jun 30, 2026 | 6,859 | 10 | |
| 2026Q1 | Mar 31, 2026 | 5,429 | 8 | |
| 2025Q4 | Dec 31, 2025 | 5,877 | 9 | |
| 2025Q3 | Sep 30, 2025 | 4,156 | 9 | |
| 2025Q2 | Jun 30, 2025 | 3,794 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,226 | 9 | |
| 2024Q4 | Dec 31, 2024 | 6,739 | 9 |
2026Q3 Earnings Call
Opening remarks
Unidentified Speaker Conference Call Disclaimer Before the conference call begins, let me remind you that during this call, management will be making comments and statements regarding its financial outlook, plans, and objectives. These statements represent forward-looking statements that involve risks and uncertainties as those terms are defined under federal securities laws. Investors are cautioned that any such forward-looking statements are not guarantees of future events, performance, or results. The company's actual results may differ materially from its current expectations. Please refer to the risks and uncertainties disclosed under the forward-looking information in today's press release, as well as the company's SEC filings, for more details on the risks and uncertainties that may cause actual results to differ materially. The company disclaims any obligation to update any forward-looking statements that may be discussed during this call, except as may be required by applicable law. You will also hear management refer to non-GAAP or adjusted measurements during this discussion. While these figures are not a substitute for GAAP measurements, management uses these figures to aid in monitoring the company's ongoing financial performance from quarter to quarter and year to year on a regular basis, and for benchmarking against other medical technology companies. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.
Operator Operator I would now like to turn the call over to Mr. Patrick J. Beyer, ConMed's president and chief executive officer. Please go ahead, sir.
Patrick J. Beyer President and CEO Thank you, operator, and welcome, everyone, to our third quarter 2026 earnings call. I am joined on the line by John E. Gallagher, our chief financial officer. Let me provide you with a quick agenda for today's call. I will start with a brief overview of our quarterly financial results. Then I will discuss the sales performance in our general and orthopedic surgery product lines, the key product growth drivers within each, and related operational highlights. John will review our financial results in detail along with our guidance for 2026, which we updated in today's press release. I will then share a few closing remarks before we open the call for questions. With that, let's get started with a review of our financial performance in the third quarter. Unless noted otherwise, all sales growth figures discussed are provided on a year-over-year and constant-currency basis. We reported net revenue of $335.6 million in the third quarter. Our net sales decreased 70 basis points on an as-reported basis and 80 basis points on a constant-currency basis. On an organic constant-currency basis, our net revenue increased 6.7% year over year.
Frequently Asked Questions About CNMD
When is CONMED's next earnings date?
CONMED's next earnings report is expected for Jan 26, 2027.
Did CNMD beat earnings estimates last quarter?
Yes. CONMED reported EPS of $1.04 for the quarter ended Sep 30, 2026, above the $1.00 estimate, a 4.00% surprise.
What EPS do analysts expect from CNMD next quarter?
The consensus EPS estimate for CONMED for the quarter ending Dec 31, 2026 is $1.29 from 9 analysts, with estimates from $1.23 to $1.33.
How often does CNMD beat earnings estimates?
CONMED beat the EPS estimate in each of the last 11 quarters, with an average surprise of +9.11%.
CNMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts